NEJM-IL-36-Phase-1-GPP-data

Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases 

Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news